Rigel Pharmaceuticals
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders, cancer, immune diseases, and other conditions. The company focuses on signaling pathways critical to disease mechanisms and has a portfolio of clinical and preclinical programs, including the FDA-approved TAVALISSE® for immune thrombocytopenia and ongoing trials for autoimmune hemolytic anemia and COVID-19. Rigel operates without physical manufacturing facilities, leveraging external expertise and partnerships to bring new therapies to patients while maintaining a commitment to regulatory compliance and patient welfare. The company emphasizes environmental sustainability, diversity, community engagement, and strong governance, with oversight from its Board of Directors and a dedicated ESG committee.
Industries
Nr. of Employees
medium (51-250)
Rigel Pharmaceuticals
611 Gateway Blvd, Suite 900, South San Francisco, CA 94080
Patents
Products
Marketed prescription therapies with prescribing information
Commercially marketed prescription therapies for indicated conditions with publicly available full prescribing information and established distribution channels.
Marketed prescription therapies with prescribing information
Commercially marketed prescription therapies for indicated conditions with publicly available full prescribing information and established distribution channels.
Services
Design and execution of clinical studies for development-stage therapies, including trial operations, site management and participant enrollment.
Operational and collaborative support for investigator-initiated studies involving company compounds.
Policy-driven review and operational handling of expanded access (compassionate use) requests for investigational therapies.
Provision of medical information via formal channels and systems for reporting adverse events and product complaints.
Consultative regulatory strategy and preparation of communications and filings to pursue expedited review pathways and formal agency interactions.
Contract negotiation and program management for collaborations, licensing arrangements and alliance oversight.
Design and execution of clinical studies for development-stage therapies, including trial operations, site management and participant enrollment.
Operational and collaborative support for investigator-initiated studies involving company compounds.
Policy-driven review and operational handling of expanded access (compassionate use) requests for investigational therapies.
Provision of medical information via formal channels and systems for reporting adverse events and product complaints.
Consultative regulatory strategy and preparation of communications and filings to pursue expedited review pathways and formal agency interactions.
Contract negotiation and program management for collaborations, licensing arrangements and alliance oversight.
Expertise Areas
- Clinical trial management and adaptive randomized trial design
- Hematology and oncology small-molecule drug development
- Translational biomarker development and mechanism-of-action studies
- Pharmacovigilance and medical information operations
Key Technologies
- Oral small-molecule kinase and signaling inhibitors
- Adaptive and randomized clinical trial methodologies
- Translational biomarker assays and immune-pathway readouts
- Pharmacovigilance and adverse event reporting systems